These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34542301)

  • 21. Characteristics and risk factors of mortality in patients with systemic sclerosis-associated interstitial lung disease.
    Jang HJ; Woo A; Kim SY; Yong SH; Park Y; Chung K; Lee SH; Leem AY; Lee SH; Kim EY; Jung JY; Kang YA; Kim YS; Park MS
    Ann Med; 2023 Dec; 55(1):663-671. PubMed ID: 37074318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
    Ueda T; Sakagami T; Kikuchi T; Takada T
    Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interstitial lung disease in systemic sclerosis: current and future treatment.
    Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
    Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis.
    Moinzadeh P; Bonella F; Oberste M; Weliwitage J; Blank N; Riemekasten G; Müller-Ladner U; Henes J; Siegert E; Günther C; Kötter I; Pfeiffer C; Schmalzing M; Zeidler G; Korsten P; Susok L; Juche A; Worm M; Jandova I; Ehrchen J; Sunderkötter C; Keyßer G; Ramming A; Schmeiser T; Kreuter A; Lorenz HM; Hunzelmann N; Kreuter M
    Chest; 2024 Jan; 165(1):132-145. PubMed ID: 37582424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between Interstitial Lung Disease Morphology Scores Based on High-resolution Computed Tomography Chest and Skin Fibrosis Degree Based on Modified Rodnan's Skin Score on Systemic Sclerosis.
    Hikmat IH; Ramdhini SS; Soekersi H; Dewi S
    Acta Med Indones; 2021 Jul; 53(3):254-260. PubMed ID: 34611063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study.
    Hamberg V; Sohrabian A; Volkmann ER; Wildt M; Löfdahl A; Wuttge DM; Hesselstrand R; Dellgren G; Westergren-Thorsson G; Rönnelid J; Andréasson K
    Arthritis Res Ther; 2023 Sep; 25(1):162. PubMed ID: 37667402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease.
    Junfei Z; Meihua G; Shuai Z; Xiangting L; Zhidan L; Tianming C; Yajing L; Chu T; Lipu S
    Clin Rheumatol; 2023 Oct; 42(10):2823-2832. PubMed ID: 37335409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection and Monitoring of Interstitial Lung Disease in Patients with Systemic Sclerosis.
    Khanna SA; Nance JW; Suliman SA
    Curr Rheumatol Rep; 2022 May; 24(5):166-173. PubMed ID: 35499699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
    Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
    Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of progression in systemic sclerosis patients with interstitial lung disease.
    Distler O; Assassi S; Cottin V; Cutolo M; Danoff SK; Denton CP; Distler JHW; Hoffmann-Vold AM; Johnson SR; Müller Ladner U; Smith V; Volkmann ER; Maher TM
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32079645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview.
    Mackintosh JA; Stainer A; Barnett JL; Renzoni EA
    Semin Respir Crit Care Med; 2019 Apr; 40(2):208-226. PubMed ID: 31137061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
    Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
    Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloid cell-specific deletion of Capns1 prevents macrophage polarization toward the M1 phenotype and reduces interstitial lung disease in the bleomycin model of systemic sclerosis.
    Zhang L; Zheng D; Yan Y; Yu Y; Chen R; Li Z; Greer PA; Peng T; Wang Q
    Arthritis Res Ther; 2022 Jun; 24(1):148. PubMed ID: 35729674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
    Jung SM; Park KS; Kim KJ
    Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonary Artery Dimensions as a Prognosticator of Transplant-Free Survival in Scleroderma Interstitial Lung Disease.
    Gleason JB; Patel KB; Hernandez F; Hadeh A; Highland KB; Rahaghi F; Mehta JP
    Lung; 2017 Aug; 195(4):403-409. PubMed ID: 28456874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rituximab treatment for systemic sclerosis-associated interstitial lung disease: a case series of 13 patients.
    Morgan K; Woollard C; Beinart D; Host LV; Roddy J
    Intern Med J; 2023 Jul; 53(7):1147-1153. PubMed ID: 35670218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
    Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
    Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study.
    Vandecasteele E; Melsens K; Vanhaecke A; Blockmans D; Bonroy C; Carton C; Deschepper E; De Keyser F; Houssiau F; Piette Y; Vanthuyne M; Verbeke K; Westhovens R; Wuyts WA; De Langhe E; Brusselle G; Smith V
    Semin Arthritis Rheum; 2021 Oct; 51(5):969-976. PubMed ID: 34403812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience.
    Henrique-Neto Á; Vasconcelos MYK; Dias JBE; de Moraes DA; Gonçalves MS; Zanin-Silva DC; Zucoloto TG; de Oliveira MFC; Dotoli GM; Weffort LF; Leopoldo VC; Oliveira MC
    Adv Rheumatol; 2021 Feb; 61(1):9. PubMed ID: 33549135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.